Skip to main content

GSK defends Zantac ahead of trials that have cratered the stock

GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation from leading drugmakers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.